Gilead Sciences announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations, such as people living with cancer or HIV. These studies evaluated routine clinical practice data from more than 800 hospitals throughout the United States to gain insights on patient outcomes as COVID-19 continues to evolve over time. These data will be presented at the 30th Conference on Retroviruses and Opportunistic Infections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead says new data from four collaborative HIV studies reported at CROI
- Kite CEO Christi Shaw leaving Gilead at end of March
- Gilead announces updated results from three cohorts of TROPHY-U-01 study
- Gilead price target raised to $101 from $88 at Mizuho
- Gilead price target raised to $95 from $90 at Cowen